Table 2.
Differentially expression of small ncRNAs in CRPC vs primary prostate cancer tissue
| CRPC vs. PCa | ||
|---|---|---|
| ncRNA | Fold change | p-value |
| miR-3687 | + 8.72 | 0.0006 |
| miR-3195 | + 5.56 | < 0.0001 |
| miR-4417 | + 5.04 | 0.0005 |
| miR-451 | + 3.85 | < 0.0001 |
| SNORD78 | + 2.47 | 0.0143 |
| miR-3156-5p | + 2.17 | 0.0040 |
| miR-194 | + 1.80 | 0.0057 |
| SNORA84 | + 1.67 | 0.1064 |
| sno-miR-78 | + 1.46 | 0.1120 |
| miR-4521 | + 1.41 | 0.0663 |
| miR-4286 | + 1.28 | 0.3183 |
| miR-3651 | + 1.21 | 0.4377 |
| SNORD49A | + 1.20 | 0.3018 |
| miR-3609 | + 1.15 | 0.5245 |
| miR-708 | + 1.08 | 0.6185 |
| miR-210 | − 1.05 | 0.9146 |
| miR-183 | − 1.10 | 0.7044 |
| miR-92b | -− 3.10 | < 0.0001 |
| miR-205 | − 4.47 | 0.0009 |
CRPC castration-resistant prostate cancer, + upregulated ncRNAs in CRPC compared to primary prostate cancer tissue (PCa), – downregulated ncRNAs in CRPC compared to primary prostate cancer
p values were calculated based on the unpaired two-tailed t-test, with Bonferroni correction